Portal de investigación
Management of high-risk prostate cancer in Spain: results from a national patterns of care survey.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Duque-Santana V
- Gómez-Aparicio MA
- Ocanto A
- Selles EG
- Gaztañaga M
- Willisch P
- Pijoan XM
- Blanco-Villar ML
- Henriquez I
- Lara PC
- Ribeiro I
- Ramirez AG
- Valcárcel ML
- de Manzanos IVF
- Echagüen SP
- Martínez PA
- Barragán VV
- Millán CV
- Vacas AI
- Ots PMS
- Glaría Enríquez LA
- Luis AM
- Niño LM
- Del Castillo Acuña R
- Del Portillo EG
- Ferrer F
- Gómez-Iturriaga A
- Del Cerro Peñalver E
- Couñago F
- López-Campos F
- URONCOR investigators
Grupos
Abstract
OBJECTIVE: The management of high-risk (HR) prostate cancer represents a challenge for radiation oncologists. This survey investigates the pattern of care in management of HR-prostate cancer across Spanish institutions. MATERIALS AND METHODS: We conducted a survey among URONCOR members from March to May 2024. This survey was structured in five sections: diagnosis, radiotherapy, hormonal treatment, follow-up, and future perspectives. RESULTS: A total of 74 responses from 71 different hospitals were received. Participants have a median professional experienced of 11 years, working most of them (84.9%) in public university hospitals. 97.3% have multidisciplinary tumor board and treat a median of 50 (0-200) HR-prostate cancer patients per year/department. 44.63% of centers use Choline-PET and 28.4% PSMA-PET at diagnosis with 26 different fractionation schedules, the most common is moderate hypofractionation (52.7%): 70 Gy in 28 fractions, followed by 37.5 Gy in 15 fractions + 15 Gy brachytherapy boost (30.4%). 56.8% of the institutions perform whole-pelvic irradiation in N0 patients, with 50.4 Gy in 28 fractions (40.48%) being the most common scheme. 56.8% prescribe an LHRH agonist and 74.6% for 24 months. 75.7% prescribe abiraterone in very high-risk patients. 63.0% use the PHOENIX-criteria to define a recurrence. 38.0% perform PSMA-PET and 39.0% Choline-PET as imaging for recurrence. After local relapse, 73.97% apply a re-irradiation technique with 11 different schedules (32.35%), with HDR-brachytherapy: 13.5 Gy × 2 being the most used (56.16%). 83.8% consider that they achieved good results in HR-prostate cancer. CONCLUSION: This study represents the current status of the management of HR-prostate cancer in Spain, highlighting the wide variety of radiotherapy treatments as well as the need for national consensus guidelines.
© 2025. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 1384-1393
- PubMed:
- 41160367
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,764 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Documentos
- No hay documentos
Filiaciones
Keywords
- High-risk prostate cancer; Hormonal treatment; PSMA-PET; Radiotherapy; SBRT
Campos de Estudio
Cita
Duque V,Gómez MA,Ocanto A,Selles EG,Gaztañaga M,Willisch P,Pijoan XM,Blanco ML,Henriquez I,Lara PC,Ribeiro I,Ramirez AG,Valcárcel ML,de Manzanos I,Echagüen SP,Martínez PA,Barragán VV,Millán CV,Vacas AI,Ots PMS,Glaría LA,Luis AM,Niño LM,Del Castillo R,Del Portillo EG,Ferrer F,Gómez A,CONDE AJ,Del Cerro E,Couñago F,López F,URONCOR I. Management of high-risk prostate cancer in Spain: results from a national patterns of care survey. Clin. Transl. Oncol. 2025. 28. (4):p. 1384-1393. IF:2,700. (3).